Amicus Therapeutics Inc.
BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal
Summary
On December 19, 2025, Amicus Therapeutics, Inc. announced that it has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical Inc. for $14.50 per share in cash, representing a total equity value of approximately $4.8 billion. The transaction, which is expected to close in the second quarter of 2026, will see Amicus become a wholly-owned subsidiary of BioMarin. The deal is expected to accelerate BioMarin's revenue growth and expand its rare disease product portfolio, adding Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease to its offerings. The acquisition is not subject to financing conditions and is subject to customary closing conditions, including regulatory approvals and stockholder approval.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement